MacPherson P
Hosp Health Netw. 1996 May 20;70(10):34-6, 38.
Will a new and, some say, improved FDA improve the conditions, financial and otherwise, of patient care? Many argue that the acceleration of the FDA approval process comes at a high price. As new drugs hit the market faster--and with less proof of their long-term benefits--health care costs are going up, up, up, and society is facing painful rationing decisions.
一个全新的、有人认为有所改进的美国食品药品监督管理局（FDA）会改善医疗护理的状况（无论是财务方面还是其他方面）吗？许多人认为，FDA审批流程的加速代价高昂。随着新药更快地进入市场，而且其长期益处的证据更少，医疗保健成本不断攀升，社会正面临痛苦的配给决策。
